Published in Am J Hematol on July 01, 2009
Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res (2009) 1.48
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther (2010) 1.29
Curative one-shot systemic virotherapy in murine myeloma. Leukemia (2012) 1.20
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant (2012) 1.06
Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther (2013) 0.95
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood (2015) 0.93
Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma (2013) 0.93
Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol (2012) 0.93
Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol (2013) 0.89
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget (2014) 0.89
Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res (2015) 0.85
Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther (2010) 0.85
Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol (2013) 0.84
Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses. Mol Ther (2015) 0.82
Myeloid neighborhood in myeloma: cancer's underbelly? Am J Hematol (2009) 0.77
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. Mol Ther Oncolytics (2016) 0.75
Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther (2017) 0.75
Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother (2013) 0.75
Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo. Front Oncol (2016) 0.75
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Macrophage polarization comes of age. Immunity (2005) 5.67
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
The origin and function of tumor-associated macrophages. Immunol Today (1992) 5.12
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol (2006) 2.33
A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion (2006) 2.04
Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res (2004) 1.98
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med (2006) 1.87
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res (2002) 1.57
Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood (1997) 1.54
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther (2007) 1.46
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther (2006) 1.43
Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol (2004) 1.43
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol (2006) 1.42
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther (2004) 1.35
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol (2007) 1.33
Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res (2003) 1.30
Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol (2003) 1.24
In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol (2000) 1.20
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene (2007) 1.18
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 1.18
Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther (2008) 1.10
Micronodular T-cell/histiocyte-rich large B-cell lymphoma of the spleen: histology, immunophenotype, and differential diagnosis. Am J Surg Pathol (2003) 1.07
Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia (2002) 1.01
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol (2007) 1.00
Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res (2003) 0.91
Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy (2004) 0.88
Multiple myeloma: an odyssey of discovery. Br J Haematol (2000) 0.88
Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia (2008) 0.86
Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. J Hematother Stem Cell Res (2000) 0.85
Myeloma bone disease: pathogenesis and treatment. Oncology (Williston Park) (2005) 0.85
Oncolytic virotherapy for multiple myeloma. Expert Opin Biol Ther (2008) 0.84
Human myeloma cells express the CD38 ligand CD31. Br J Haematol (1999) 0.78
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet (2005) 4.09
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood (2009) 3.00
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood (2005) 2.54
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Plasmablastic lymphoma and related disorders. Am J Clin Pathol (2011) 2.44
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood (2010) 2.40
Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2010) 2.38
IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol (2010) 2.35
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
A review of POEMS syndrome. Oncology (Williston Park) (2013) 2.25
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate (2010) 2.22
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology (Williston Park) (2012) 2.18
Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging (2012) 2.16
Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 2.14
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood (2003) 2.12
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Screening panels for detection of monoclonal gammopathies. Clin Chem (2009) 2.05
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer (2006) 2.00
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood (2006) 1.98
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood (2010) 1.98
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood (2006) 1.95
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood (2005) 1.91
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood (2009) 1.90
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc (2009) 1.88
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood (2005) 1.87
Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc (2006) 1.87